AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca total equity ($M) ($M)
Consolidated Statement of Financial Position (Postgres DB)
Latest, Q2 2026
50,370
Period ended Jun 30, 2026
Change on a year earlier
+12.4%
44,810 in Q2 2025
History
22 quarters
Since Q4 2014
Sources
18
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total equity ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 50,370 | +12.4% | Form 6-K (filed 2026-07-27) ↗ |
| Q4 2025 | Dec 31, 2025 | 48,719 | +19.2% | Form 20-F (filed 2026-02-24) ↗ |
| Q2 2025 | Jun 30, 2025 | 44,810 | +13.2% | Form 6-K (filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 40,871 | +4.4% | Form 20-F (filed 2025-02-18) ↗ |
| Q2 2024 | Jun 30, 2024 | 39,598 | +5.8% | Form 6-K (filed 2024-07-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 39,166 | +5.7% | Form 20-F (filed 2024-02-20) ↗ |
| Q2 2023 | Jun 30, 2023 | 37,416 | +4.1% | Form 6-K (filed 2023-07-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 37,058 | -5.7% | Form 20-F (filed 2023-02-21) ↗ |
| Q2 2022 | Jun 30, 2022 | 35,951 | +129.1% | Form 6-K (filed 2022-07-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 39,287 | +151.2% | Form 20-F (filed 2022-02-22) ↗ |
| Q2 2021 | Jun 30, 2021 | 15,693 | +14.9% | Form 6-K (filed 2021-07-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 15,638 | +7.1% | Form 20-F (filed 2021-02-16) ↗ |
| Q2 2020 | Jun 30, 2020 | 13,658 | -9.4% | Form 6-K/A (filed 2020-07-31) ↗ |
| Q4 2019 | Dec 31, 2019 | 14,596 | +3.9% | Form 20-F (filed 2020-03-03) ↗ |
| Q2 2019 | Jun 30, 2019 | 15,071 | +5.6% | Form 6-K (filed 2019-07-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 14,044 | -15.6% | Form 20-F (filed 2019-03-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 14,272 | -7.4% | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2017 | Dec 31, 2017 | 16,642 | -0.2% | Form 20-F (filed 2018-03-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 15,412 | – | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 16,669 | -9.9% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 18,509 | -5.8% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2014 | Dec 31, 2014 | 19,646 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up total equity ($m)
Cite this data
StockData. (2026). AstraZeneca Total equity ($M) ($M), quarterly Q4 2014–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_equity
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.